Please assess the completion status of the following clinical trial:

Trial Title: Aortix Therapy for Perioperative Reduction of Kidney Injury

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have the following risk factor(s) for AKI prior to surgery:~   1. Estimated glomerular filtration rate (eGFR) of ≥ 15 and \< 30 ml/min/1.73m2, OR~  2. eGFR ≥ 30 and \< 60 ml/min/1.73m2 and ONE or more of the following:~      1. Diabetes (regardless of cause) with metabolic, renal, ophthalmic, neurologic, circulatory, or other complications~     2. Documented NYHA class III or IV heart failure within 1 year prior to enrollment~     3. Left ventricular ejection fraction \< 35%~     4. Hypertension with comorbid heart or kidney disease~     5. Persistent Atrial Fibrillation~2. Planned (non-emergency) cardiac surgical procedure including, but not limited to coronary bypass surgery, surgical valve replacement or valve repair~3. Age \>21 years, willing and able to provide written informed consent.~   -~Exclusion Criteria:~1. An eGFR of \<15 ml/min/1.73m2 at enrollment~2. Cardiac surgical procedure that uses femoral artery cannulation for cardiopulmonary bypass~3. Current support with a durable LVAD, intra-aortic balloon pump, extracorporeal membrane oxygenation (ECMO), or percutaneous ventricular assist devices (e.g., Impella or TandemHeart)~4. Patient has known hypo- or hyper-coagulable state such as disseminated intravascular coagulation or heparin induced thrombocytopenia (HIT)~5. Endovascular procedure with ilio-femoral access \>12F within previous 30 days~6. Severe Bleeding Risk (any of the following):~   1. Previous intracranial bleed such that the patient cannot safely use anticoagulation per the study requirements~  2. Platelet count \<75,000 cells/mm3~  3. Uncorrectable bleeding diathesis or coagulopathy (e.g., INR ≥ 2 not due to anticoagulation therapy~7. Current endovascular stent graft in the descending aorta or either ilio-femoral vessels~8. Contraindicated Anatomy:~   1. Descending aortic anatomy that would prevent safe placement of the device \[\<18 mm or \>31 mm aorta diameter at deployment location (measured between the superior aspect of the T10 vertebra and superior aspect of the L1 vertebra)\]~  2. Ilio-femoral diameter or peripheral vascular anatomy that would preclude safe placement of a 21F (outer diameter) introducer sheath~  3. Abnormalities or severe vascular disease that would preclude safe access and device delivery (e.g., aneurysm with thrombus; marked tortuosity; significant narrowing or inadequate size of the abdominal aorta, iliac, or femoral arteries; or severe calcification)~  4. Known connective tissue disorder (e.g., Marfan Syndrome) or other aortopathy at risk of vascular injury~9. Known hypersensitivity or contraindication to study required medications (e.g., anticoagulation therapy) or device materials (e.g., history of severe reaction to nickel or nitinol)~10. Positive pregnancy test if of childbearing potential~11. Participation in any other clinical investigation that is likely to confound study results or affect the study~    -

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aortix Arm (Type: EXPERIMENTAL): Subject receives the Aortix device.
- Non-Aortix Arm (Type: NO_INTERVENTION): Control Arm consists of subjects who choose not to receive the Aortix device or who do not meet the anatomical requirements to receive the Aortix device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues